Yi Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yi Feng has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Keith Gordon Harding
Cardiff University Cardiff UK
3 shared publications - Shuqin Jia
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research Center for Molecular Diagnosis, Peking University Cancer Hospital & Institute Beijing, Beijing, China
3 shared publications - Wen Guo Jiang
Cardiff University
3 shared publications Andrew J. Sanders
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK
2 shared publicationsFiona Ruge
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK
2 shared publications- Hui Chen
College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 12, e67476
Need Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study
Background: The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs. A lack of comprehensive needs assessment may result in unaddressed requirements, limiting the effectiveness of these tools in real-world practice. Objective: This study aimed to explore clinicians’ needs and expectations regarding the functionalities of integrated PODS tools, providing insights into essential features that could enhance their usability and impact. Methods: We conducted a qualitative investigation at Peking University Cancer Hospital to explore clinicians’ needs and expectations for the functions of integrated PODS tools. Data were collected through 143 structured participant observations during multidisciplinary team meetings and 17 in-depth semistructured interviews with a diverse group of oncology specialists, including physicians, surgeons, molecular biologists, radiotherapists, radiologists, and pathologists. Thematic analysis was applied to identify key functional requirements, and a requirements framework was formed. Results: Three overarching functional needs emerged: (1) better access to oncological knowledge, including support for therapy selection (guidelines, conferences, and consensuses), clinical trials, drug and treatment information, and complex case knowledge, as well as improved diagnostic and prognostic insights; (2) clinical contextualization and resource navigation, referring to the process of contextualizing scientific knowledge within real-world clinical settings, including access to clinical trials and drugs, along with predictive models for treatment response; and (3) support abilities in the decision-making process, highlighting the need for integration of flexible biological knowledge and phenotypic data; automated patient information synthesis; improved data visualization; and optimized retrieval, recommendation, and question-answering functionalities. A functional framework for integrated PODS tools was proposed based on these findings. Conclusions: The study conducted a qualitative descriptive observation and interview in the use, needs of integrated PODS tools. PODS tools serve as complex, multilevel decision support systems. A clear understanding of clinicians’ actual needs is crucial for their refinement and practical adoption. By capturing perspectives directly from oncology professionals, this study provides actionable insights into the functional enhancements required for PODS tools, ultimately aiming to bridge the gap between genomic advancements and clinical decision-making in precision oncology.
- 8 September 2025
- Published by JMIR Publications Inc. in JMIR Human Factors
- Vol. 12, e67476
Open AccessNeed Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study
Background: The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs. A lack of comprehensive needs assessment may result in unaddressed requirements, limiting the effectiveness of these tools in real-world practice. Objective: This study aimed to explore clinicians’ needs and expectations regarding the functionalities of integrated PODS tools, providing insights into essential features that could enhance their usability and impact. Methods: We conducted a qualitative investigation at Peking University Cancer Hospital to explore clinicians’ needs and expectations for the functions of integrated PODS tools. Data were collected through 143 structured participant observations during multidisciplinary team meetings and 17 in-depth semistructured interviews with a diverse group of oncology specialists, including physicians, surgeons, molecular biologists, radiotherapists, radiologists, and pathologists. Thematic analysis was applied to identify key functional requirements, and a requirements framework was formed. Results: Three overarching functional needs emerged: (1) better access to oncological knowledge, including support for therapy selection (guidelines, conferences, and consensuses), clinical trials, drug and treatment information, and complex case knowledge, as well as improved diagnostic and prognostic insights; (2) clinical contextualization and resource navigation, referring to the process of contextualizing scientific knowledge within real-world clinical settings, including access to clinical trials and drugs, along with predictive models for treatment response; and (3) support abilities in the decision-making process, highlighting the need for integration of flexible biological knowledge and phenotypic data; automated patient information synthesis; improved data visualization; and optimized retrieval, recommendation, and question-answering functionalities. A functional framework for integrated PODS tools was proposed based on these findings. Conclusions: The study conducted a qualitative descriptive observation and interview in the use, needs of integrated PODS tools. PODS tools serve as complex, multilevel decision support systems. A clear understanding of clinicians’ actual needs is crucial for their refinement and practical adoption. By capturing perspectives directly from oncology professionals, this study provides actionable insights into the functional enhancements required for PODS tools, ultimately aiming to bridge the gap between genomic advancements and clinical decision-making in precision oncology.
- Open Access
- 14 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Need Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study (Preprint)
BACKGROUND The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs. A lack of comprehensive needs assessment may result in unaddressed requirements, limiting the effectiveness of these tools in real-world practice. OBJECTIVE This study aimed to explore clinicians’ needs and expectations regarding the functionalities of integrated PODS tools, providing insights into essential features that could enhance their usability and impact. METHODS We conducted a qualitative investigation at Peking University Cancer Hospital to explore clinicians’ needs and expectations for the functions of integrated PODS tools. Data were collected through 143 structured participant observations during multidisciplinary team meetings and 17 in-depth semistructured interviews with a diverse group of oncology specialists, including physicians, surgeons, molecular biologists, radiotherapists, radiologists, and pathologists. Thematic analysis was applied to identify key functional requirements, and a requirements framework was formed. RESULTS Three overarching functional needs emerged: (1) better access to oncological knowledge, including support for therapy selection (guidelines, conferences, and consensuses), clinical trials, drug and treatment information, and complex case knowledge, as well as improved diagnostic and prognostic insights; (2) clinical contextualization and resource navigation, referring to the process of contextualizing scientific knowledge within real-world clinical settings, including access to clinical trials and drugs, along with predictive models for treatment response; and (3) support abilities in the decision-making process, highlighting the need for integration of flexible biological knowledge and phenotypic data; automated patient information synthesis; improved data visualization; and optimized retrieval, recommendation, and question-answering functionalities. A functional framework for integrated PODS tools was proposed based on these findings. CONCLUSIONS The study conducted a qualitative descriptive observation and interview in the use, needs of integrated PODS tools. PODS tools serve as complex, multilevel decision support systems. A clear understanding of clinicians’ actual needs is crucial for their refinement and practical adoption. By capturing perspectives directly from oncology professionals, this study provides actionable insights into the functional enhancements required for PODS tools, ultimately aiming to bridge the gap between genomic advancements and clinical decision-making in precision oncology. CLINICALTRIAL
- 14 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessNeed Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study (Preprint)
BACKGROUND The rapid advancement of next-generation sequencing has significantly expanded the landscape of precision medicine. However, health care professionals face increasing challenges in keeping pace with the growing body of oncological knowledge and integrating it effectively into clinical workflows. Precision oncology decision support (PODS) tools aim to assist clinicians in navigating this complexity, yet their current functionalities only partially address clinical needs. A lack of comprehensive needs assessment may result in unaddressed requirements, limiting the effectiveness of these tools in real-world practice. OBJECTIVE This study aimed to explore clinicians’ needs and expectations regarding the functionalities of integrated PODS tools, providing insights into essential features that could enhance their usability and impact. METHODS We conducted a qualitative investigation at Peking University Cancer Hospital to explore clinicians’ needs and expectations for the functions of integrated PODS tools. Data were collected through 143 structured participant observations during multidisciplinary team meetings and 17 in-depth semistructured interviews with a diverse group of oncology specialists, including physicians, surgeons, molecular biologists, radiotherapists, radiologists, and pathologists. Thematic analysis was applied to identify key functional requirements, and a requirements framework was formed. RESULTS Three overarching functional needs emerged: (1) better access to oncological knowledge, including support for therapy selection (guidelines, conferences, and consensuses), clinical trials, drug and treatment information, and complex case knowledge, as well as improved diagnostic and prognostic insights; (2) clinical contextualization and resource navigation, referring to the process of contextualizing scientific knowledge within real-world clinical settings, including access to clinical trials and drugs, along with predictive models for treatment response; and (3) support abilities in the decision-making process, highlighting the need for integration of flexible biological knowledge and phenotypic data; automated patient information synthesis; improved data visualization; and optimized retrieval, recommendation, and question-answering functionalities. A functional framework for integrated PODS tools was proposed based on these findings. CONCLUSIONS The study conducted a qualitative descriptive observation and interview in the use, needs of integrated PODS tools. PODS tools serve as complex, multilevel decision support systems. A clear understanding of clinicians’ actual needs is crucial for their refinement and practical adoption. By capturing perspectives directly from oncology professionals, this study provides actionable insights into the functional enhancements required for PODS tools, ultimately aiming to bridge the gap between genomic advancements and clinical decision-making in precision oncology. CLINICALTRIAL
- Open Access
- 10 July 2020
- Published by Springer Nature in Research Square
Investigation on Gastric Cancer Susceptibility Genes in Chinese Early-onset Diffuse Gastric Cancer
BackgroundDiffuse gastric cancer (DGC) is known as gastric cancer with diffuse type morphology. Early onset DGC is an indicator of suspicious hereditary diffuse gastric cancer (HDGC). HDGC patient are often less sensitive to chemotherapy and suffer from highly invasive late stage malignancy with poor prognosis. Such hereditary cancer syndrome is closely related to deleterious CDH1 germline variant. In addition, potential pathogenic germline variants in other candidate genes were also observed in HDGC families. However, the profile of gastric cancer (GC) susceptibility gene in Chinese HDGC patients is yet to be elucidated.MethodsTo investigate gastric cancer susceptibility genes in Chinese gastric cancer patients, we collected peripheral blood samples from 29 patients fulfilled both HDGC clinical diagnosis and genetic testing criteria updated on 2015 by IGCLC. Genomic DNA was extracted from peripheral blood followed by Whole Exome Sequencing (WES) with average sequencing depth of at least 100X. Gastric cancer predisposing SNV and Indel candidates were filtered based on population allele frequencies in public nucleotide polymorphism databases and pathogenic variant filtering process was performed to identify potential gastric cancer predisposing variant candidates. Immunohistochemistry was conducted on biopsies from patient who carries potential pathogenic CDH1 germline variant.ResultsIn general, 336296 germline non-synonymous variants were detected from 29 GC patients. According to the pathogenic variant filtering process, 25 germline variant candidates in 22 genes were identified as gastric cancer predisposing variant candidates. In addition, a novel splice-site variant, c.2165-1G>A (NM_004360.4), in CDH1 was detected in a Chinese early-onset HDGC patient who developed ovarian metastasis. Furthermore, IHC analysis on the ovarian cancer tissue from this patient demonstrated weakly to moderate staining of E-cadherin compared with positive control. Moreover, another two variants, CTNNA1 c.1975_1976del (NM_001903.2), APC c.-19+1G>A (NM_001127511.2), were suspicious of gastric cancer predisposing variants.ConclusionsThis study suggested that CDH1 c.2165-1G>A may act as a gastric cancer predisposing variant. In addition, to further investigate molecular mechanisms of early-onset gastric cancer, one may consider 22 genes observed in this study. Furthermore, the inconclusive results in this study warrant future investigation on gastric cancer susceptibility gene discovery that cohort selection may require more stringent conditions.
- 10 July 2020
- Published by Springer Nature in Research Square
Open AccessInvestigation on Gastric Cancer Susceptibility Genes in Chinese Early-onset Diffuse Gastric Cancer
BackgroundDiffuse gastric cancer (DGC) is known as gastric cancer with diffuse type morphology. Early onset DGC is an indicator of suspicious hereditary diffuse gastric cancer (HDGC). HDGC patient are often less sensitive to chemotherapy and suffer from highly invasive late stage malignancy with poor prognosis. Such hereditary cancer syndrome is closely related to deleterious CDH1 germline variant. In addition, potential pathogenic germline variants in other candidate genes were also observed in HDGC families. However, the profile of gastric cancer (GC) susceptibility gene in Chinese HDGC patients is yet to be elucidated.MethodsTo investigate gastric cancer susceptibility genes in Chinese gastric cancer patients, we collected peripheral blood samples from 29 patients fulfilled both HDGC clinical diagnosis and genetic testing criteria updated on 2015 by IGCLC. Genomic DNA was extracted from peripheral blood followed by Whole Exome Sequencing (WES) with average sequencing depth of at least 100X. Gastric cancer predisposing SNV and Indel candidates were filtered based on population allele frequencies in public nucleotide polymorphism databases and pathogenic variant filtering process was performed to identify potential gastric cancer predisposing variant candidates. Immunohistochemistry was conducted on biopsies from patient who carries potential pathogenic CDH1 germline variant.ResultsIn general, 336296 germline non-synonymous variants were detected from 29 GC patients. According to the pathogenic variant filtering process, 25 germline variant candidates in 22 genes were identified as gastric cancer predisposing variant candidates. In addition, a novel splice-site variant, c.2165-1G>A (NM_004360.4), in CDH1 was detected in a Chinese early-onset HDGC patient who developed ovarian metastasis. Furthermore, IHC analysis on the ovarian cancer tissue from this patient demonstrated weakly to moderate staining of E-cadherin compared with positive control. Moreover, another two variants, CTNNA1 c.1975_1976del (NM_001903.2), APC c.-19+1G>A (NM_001127511.2), were suspicious of gastric cancer predisposing variants.ConclusionsThis study suggested that CDH1 c.2165-1G>A may act as a gastric cancer predisposing variant. In addition, to further investigate molecular mechanisms of early-onset gastric cancer, one may consider 22 genes observed in this study. Furthermore, the inconclusive results in this study warrant future investigation on gastric cancer susceptibility gene discovery that cohort selection may require more stringent conditions.
- Open Access
- 27 July 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 6715
In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing
Wound healing and the management of chronic wounds represent a significant burden on the NHS. Members of the suppressor of cytokine signalling (SOCS) family have been implicated in the regulation of a range of cellular processes. The current study aims to explore the importance of SOCS-3 and SOCS-4 in regulating cellular traits associated with wound healing. SOCS-3 over-expression and SOCS-4 knockdown mutant lines were generated and verified using q-PCR and western blotting in human keratinocytes (HaCaT) and endothelial cells (HECV). Over-expression of SOCS-3 resulted in a significantly reduced proliferative rate in HaCaT keratinocytes and also enhanced the tubule formation capacity of HECV cells. SOCS-4 knockdown significantly reduced HaCaT migration and HECV cell tubule formation. Suppression of SOCS-4 influenced the responsiveness of HaCaT and HECV cells to EGF and TGFβ and resulted in a dysregulation of phospho-protein expression in HaCaT cells. SOCS-3 and SOCS-4 appear to play regulatory roles in a number of keratinocyte and endothelial cellular traits associated with the wound healing process and may also be able to regulate the responsiveness of these cells to EGF and TGFβ. This implies a potential regulatory role in the wound healing process and, thus highlights their potential as novel therapies.
- 27 July 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 6715
Open AccessIn vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing
Wound healing and the management of chronic wounds represent a significant burden on the NHS. Members of the suppressor of cytokine signalling (SOCS) family have been implicated in the regulation of a range of cellular processes. The current study aims to explore the importance of SOCS-3 and SOCS-4 in regulating cellular traits associated with wound healing. SOCS-3 over-expression and SOCS-4 knockdown mutant lines were generated and verified using q-PCR and western blotting in human keratinocytes (HaCaT) and endothelial cells (HECV). Over-expression of SOCS-3 resulted in a significantly reduced proliferative rate in HaCaT keratinocytes and also enhanced the tubule formation capacity of HECV cells. SOCS-4 knockdown significantly reduced HaCaT migration and HECV cell tubule formation. Suppression of SOCS-4 influenced the responsiveness of HaCaT and HECV cells to EGF and TGFβ and resulted in a dysregulation of phospho-protein expression in HaCaT cells. SOCS-3 and SOCS-4 appear to play regulatory roles in a number of keratinocyte and endothelial cellular traits associated with the wound healing process and may also be able to regulate the responsiveness of these cells to EGF and TGFβ. This implies a potential regulatory role in the wound healing process and, thus highlights their potential as novel therapies.
- Open Access
- 13 September 2016
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 38 (5) , 1349-1358
Expression of the SOCS family in human chronic wound tissues: Potential implications for SOCS in chronic wound healing
Cytokines play important roles in the wound healing process through various signalling pathways. The JAK-STAT pathway is utilised by most cytokines for signal transduction and is regulated by a variety of molecules, including suppressor of cytokine signalling (SOCS) proteins. SOCS are associated with inflammatory diseases and have an impact on cytokines, growth factors and key cell types involved in the wound‑healing process. SOCS, a negative regulator of cytokine signalling, may hold the potential to regulate cytokine‑induced signalling in the chronic wound‑healing process. Wound edge tissues were collected from chronic venous leg ulcer patients and classified as non-healing and healing wounds. The expression pattern of seven SOCSs members, at the transcript and protein level, were examined in these tissues using qPCR and immunohistochemistry. Significantly higher levels of SOCS3 (P=0.0284) and SOCS4 (P=0.0376) in non-healing chronic wounds compared to the healing/healed chronic wounds were observed at the transcript level. Relocalisation of SOCS3 protein in the non-healing wound environment was evident in the investigated chronic biopsies. Thus, the results show that the expression of SOCS transcript indicated that SOCS members may act as a prognostic biomarker of chronic wounds.
- 13 September 2016
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 38 (5) , 1349-1358
Open AccessExpression of the SOCS family in human chronic wound tissues: Potential implications for SOCS in chronic wound healing
Cytokines play important roles in the wound healing process through various signalling pathways. The JAK-STAT pathway is utilised by most cytokines for signal transduction and is regulated by a variety of molecules, including suppressor of cytokine signalling (SOCS) proteins. SOCS are associated with inflammatory diseases and have an impact on cytokines, growth factors and key cell types involved in the wound‑healing process. SOCS, a negative regulator of cytokine signalling, may hold the potential to regulate cytokine‑induced signalling in the chronic wound‑healing process. Wound edge tissues were collected from chronic venous leg ulcer patients and classified as non-healing and healing wounds. The expression pattern of seven SOCSs members, at the transcript and protein level, were examined in these tissues using qPCR and immunohistochemistry. Significantly higher levels of SOCS3 (P=0.0284) and SOCS4 (P=0.0376) in non-healing chronic wounds compared to the healing/healed chronic wounds were observed at the transcript level. Relocalisation of SOCS3 protein in the non-healing wound environment was evident in the investigated chronic biopsies. Thus, the results show that the expression of SOCS transcript indicated that SOCS members may act as a prognostic biomarker of chronic wounds.
- 15 February 2016
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 11 (2) , 193-209
Potential Roles of Suppressor of Cytokine Signaling in Wound Healing
Wound healing is a dynamic process comprising three overlapping, highly orchestrated stages known as inflammation, proliferation and re-epithelialization, and tissue remodeling. This complex process is regulated by numerous cytokines, with dysregulation of cytokine-induced signaling leading to impaired wound healing. Suppressor of cytokine signaling (SOCS) proteins are a family of eight intracellular proteins which may hold the potential to maintain homeostasis during wound healing through their negative feedback inhibition of cytokine signaling. To date, the roles of SOCS proteins in inflammation, autoimmunity and cancer have been comprehensively illustrated; however, only a limited number of studies focused on their role in wound healing. This review demonstrates the possible links between SOCS proteins and wound healing, and also highlights the potential importance of this family in a variety of other aspects of regenerative medicine.
- 15 February 2016
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 11 (2) , 193-209
Potential Roles of Suppressor of Cytokine Signaling in Wound Healing
Wound healing is a dynamic process comprising three overlapping, highly orchestrated stages known as inflammation, proliferation and re-epithelialization, and tissue remodeling. This complex process is regulated by numerous cytokines, with dysregulation of cytokine-induced signaling leading to impaired wound healing. Suppressor of cytokine signaling (SOCS) proteins are a family of eight intracellular proteins which may hold the potential to maintain homeostasis during wound healing through their negative feedback inhibition of cytokine signaling. To date, the roles of SOCS proteins in inflammation, autoimmunity and cancer have been comprehensively illustrated; however, only a limited number of studies focused on their role in wound healing. This review demonstrates the possible links between SOCS proteins and wound healing, and also highlights the potential importance of this family in a variety of other aspects of regenerative medicine.